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iAbstract
Diabetes is a chronic disease which affects more than 60 million people only in
Europe and is set to become one of the mass diseases in the near future. This
disorder has serious short and long-term implications and requires life-long attention
to many aspects, blood glucose monitoring and meal planning and insulin injections.
This is true especially for patient with Type 1 Diabetes, which have to manage their
disease the whole life.
The therapy is based on multiple daily exogenous insulin administrations tuned
according to blood-glucose (BG) measurements, made by the patient himself or
with an autonomous sensor. In recent years many research projects have focused
on easing the patient’s quality of life while increasing the control on glucose levels.
Many projects involve the development of new algorithms that help the patient
taking therapy decisions. All this new techniques have to be tested in order to
verify their actual usability and improvements in blood glucose control.
The Biomedical engineering research group in Padua has been developing some new
algorithms and there was the need for a platform that would have allowed an easy
testing in clinical trials.
In this thesis we developed a prototype of this such platform, in the form of a
mobile application where the patient can track all his data and the algorithm can
be deployed to be tested. We also developed a website for clinicians to track patients
levels in real time during trials. This platform allows also to save all gathered data
for later use in simulations to develop even more optimized algorithms. The whole
platform has been developed to fulfill requirements in privacy and usability.
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Chapter 1
Mobile health applications for
diabetes management
During the last few years, the interest for the development and creation of medical
applications to be used in mobile technologies has increased more and more due to the
wide availability and diffusion of smartphones. So far, total of 80% to 90% of adults
in the United States and 75% of adults worldwide currently own a smartphone [1].
Nowadays, a smartphone is the preferred device among the adult people to access an
app, 53% of adults using them for such a purpose, while desktop computers are used
one-third of the time or less for the same purpose [2].
mHealth, which stands for mobile health, is the term used to define mobile communi-
cation devices for health support activities [3]. mHealth has many different purposes,
which span from remote monitoring to decision support, from easier and enhanced ac-
cess to patient data to reminders of therapy need. From the literature point of view,
mHealth topic has had a three-fold increase in publications between 2010 and 2016 re-
maining stable after that year, this is due to the increasing interest by research groups,
doctors and patients on the topic [4].
The main target of mHealth and telemedicine is to keep healthy patients at home,
reducing the need to move to healthcare facilities for control visits, and to give sick
patients early and tempestive care. This allows to reduce healthcare costs and to improve
the success rate of prevention campaigns and survivability of sick patients by increasing
focused efforts by doctors. Some evidence shows that the use of mHealth increases
new patient capture decreasing at the same time, health care costs as the number of
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patients that are actively treated is reduced [5]. Other findings have shown that pediatric
telemedicine significantly reduced emergency ward and urgent care usage [6].
According to the latest e-health report “From innovation to implementation – e-health
in the WHO European Region” [7] by World Health Organization Europe, health au-
thorities of about half of the countries in the European region promote the development
and adoption of mHealth in the health sector. The report further shows that when
governments sponsor mHealth programs, they are also more likely to provide incentives
and guidance on innovation and evaluation, as well as regulation for their use. Many
telehealth projects in the European Region are now progressing from pilot projects to
broad-scale implementation. Realizing the public demand for telehealth, larger regional
telehealth initiatives are emerging. The main fields of actual telehealth working projects
are teleradiology, telepathology and remote patient monitoring.
In Italy a recent article about telemedicine remarks how healthcare has a major im-
pact on state expenses, up to 10% of GDE goes to healthcare [8]. This value is going
to raise due to increasing of average age of the population and increasing incidence of
chronic diseases. Investments in mHealth, in particular in telemedicine, can avoid an
enormous impact on state finances, keeping costs stable and even increasing care quality
and equality. Mobile medical application can result very useful in the management of
chronic diseases, reducing the effort needed by patient to manage their condition. In
Italy health app and wearable devices are widely spreading. Italy is the second most fre-
quent worldwide user of new technology, particularly wearables, after the United States
and before Germany and France [9]. A recent survey shows that, in Italy, health apps
and wearable devices are sufficiently known and used by the adult population and are
considered potential supports for greater involvement in health management. Mobile ap-
plications are valued especially for their usefulness to improve patients’ engagement and
compliance with treatment, while wearables are mainly used to check physical activity
and glycemia. The main obstacles for the diffusion of mobiles and mobile applications
are personal or technical reasons, with a high concern on overmedicalization in the long
period [10].
1.1 Type 1 diabetes mellitus
Diabetes Mellitus is a chronic metabolic disease caused either by deficiency in produc-
tion of insulin by the pancreas’ cells or by the ineffectiveness of the insulin produced or
both. Diabetes Mellitus causes an inefficient or absent control of glucose levels in blood,
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thus leading to hyperglycemia. Symptoms of marked hyperglycemia include polyuria
(frequent urination), polydipsia (thirst), weight loss, sometimes with polyphagia (con-
tinuous sense of hunger), and blurred vision. Impairment of growth and susceptibility to
certain infections may also accompany chronic hyperglycemia. Acute, life-threatening
consequences of diabetes are hyperglycemia with ketoacidosis (uncontrolled production
of ketone bodies causing blood PH fluctuations), most severe forms can include coma
and even death. Diabetes Mellitus complications can be either acute or chronic. The
chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and
failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels
[11]. Overall, complications are far less severe in people with well-controlled blood sugar
levels [12].
The majority of cases of diabetes fall into two broad categories. In one category (type
1 diabetes), the cause is an absolute deficiency of insulin secretion. In the other, much
more prevalent category (type 2 diabetes), the cause is a combination of resistance to
insulin action and an inadequate compensatory insulin secretory response. In the latter
category, a degree of hyperglycemia sufficient to cause pathologic and functional changes
in various target tissues, but without clinical symptoms, may be present for a long period
of time before diabetes is detected. There is also a third category which affects women
during pregnancy and is called gestational diabetes, but has a much lower incidence than
the two cited categories.
Type 1 Diabetes (T1D), formerly known as insulin-dependent, in which there is the
destruction of pancreas’ β-cells, whose role is insulin production. T1D is an au-
toimmune disorder and affects about 10% of patients: usually it appears during
childhood or adolescence, but it can begin in adults too. All the patients need to
take insulin injections for the rest of their life (insulin-dependency) and to follow
a special diet. Despite active research, T1D has no cure, but it can be managed.
Type 2 Diabetes (T2D), formerly named insulin-independent, results from the body’s
inability to respond properly to the action of insulin produced by the pancreas.
It develops most frequently in adults, when the body becomes resistant to insulin
or if the pancreas doesn’t produce enough insulin to keep blood glucose at normal
levels, causing hyperglycemia. The risk of developing T2D increases with obesity,
sedentary life and wrong diet. Patients are not required to do lifelong insulin treat-
ment but can control blood glucose with healthy food and exercise, combined with
oral drugs or addition of insulin as needed at least in the early phases of the dis-
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ease [11]. T2D is more common and accounts for around 90% of all diabetes cases
worldwide. It occurs more frequently in women with prior Gestational Diabetes
and in individuals with hypertension or dyslipidemia (high fat levels in blood),
and its frequency varies in different racial/ethnic subgroups [11]. There is also a
genetic predisposition to the disease but it’s form is complex and not well defined
yet.
Gestational Diabetes (GD), affects women during pregnancy but usually resolves
itself after childbirth. Since blood with high glucose levels circulates through
the placenta to the baby, this form of diabetes must be controlled to protect the
baby growth. Gestational diabetes increases the risk of congenital malformations,
breathing problems and increased weight at birth.
This work focuses mostly on T1D because it is object of several studies for its high risk
and mortality rate.
1.1.1 T1D therapy
Type 1 diabetes get diagnosed usually during childhood or early adolescences and from
that point on the patient has to learn how to cope with it.
The standard T1D therapy is an ”open-loop” control approach that tries to maintain
the blood glucose concentration in the euglycemic range (70-180 mg/dL) during the day.
Particular attention is given to avoid the hypoglycemic episodes given their dangerous-
ness for the patient. The control is obtained with multiple injections of insulin, usually
at meal time, in quantity based on the meal, physical activity and current blood glu-
cose concentration. This is measured by the patient with self-monitoring blood glucose
(SMBG) samples taken with a fingerstick device (shown in Figure 1.1) three to five times
a day.
Insulin injection’s quantities are estimated with some rules that have to be fine tuned for
each patient. This rules are usually kept easy in formula to allow patients to perform the
calculation on the fly, but there are some devices and mobile applications that perform
the calculations and advice the patient on insulin doses. This applications are the basic
format of decision support systems.
The fingerstick process is burdensome for the patients and finger skin gets harder and
thicker the more the procedure is repeated. This is why in recent years there is a
new technology that is being used more and more by the patients: Continuous Glucose
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Figure 1.1: Fingerstick device
Monitoring (CGM) devices. This devices are small sensors that are applied on the skin
of the patient and thanks to a micro-needle sensor placed in the subcutis are able to
measure the blood glucose (BG) concentration every few minutes.
This higher frequency of BG values allows the patient to keep track of his levels easier and
without the need of manually prick himself. It is also possible to have some informations
about trends and change the insulin dose accordingly. Having more data allows also to
detect dangerous events that would have otherwise been missed as can be seen in figure
1.2 where the hyper and hypo-glycemic events would not have been detected with SMBG
only.
1.1.2 Problems of the standard therapy
The standard therapy has some disadvantages and problems which leave space of im-
provement. As said, patients have to live with the burden of the measurement need
multiple times every day and may have a lack of motivation and education to under-
stand the results of the measure. The patient has to complete at least 3 sequences of
tasks everyday, involving for each meal two measures (before and after the meal) and at
least one insulin injection (meal bolus and corrective if needed). The amount of tasks
performed by a patient in therapy exceeds 500.000 during his whole life. CGM allows
to reduce the number of this tasks and allows to have measures during nighttime, which
would otherwise be unmeasured.
Insulin bolus calculation has high chance of error. The used formulas optimally tuned
in a given time instant could be suboptimal later on because of the natural variability
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Figure 1.2: 24 hours of glycemic monitoring using SMBG (red dots) and CGM (blue
line). CGM allows to detect hyper/hypo events which are not tracked by SMBG. [13]
of patient’s physiology (e.g. variantions in insulin sensitivity), whose fluctiations could
happen also within a single day. The standard formula for meal insulin bolus does not
take into account all parameters influencing glucose use during different activities in
addition, meal absorption times and carbohydrates estimate are key parameters whose
wrong estimation can lead to large errors in insulin dose. Finally, physical activity,
sleep and stress are other influencing factors which are not taken in consideration in
standard control approach. New approaches and more advanced techniques to evaluate
different data sources are needed to acquire such important information, to improve e.g.
insulin dosing and perform a better control. Mobile health is one of the most promising
solutions in which most of the new techniques can be summarized in decision support
systems.
1.2 mHealth and diabetes
In Europe there are 60 million people living with diabetes and 32 million more are
at risk [14], thus diabetes has been a major target for medical software companies.
Diabetes is one of the future mass diseases, thus the research and development of mHealth
techniques targeting affected patients aims to improve their lifestyle and management
of the disease.
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mHealth for diabetes is mainly focused on:
• Real time monitoring of patients’ status
• Decision support for patients on activities and insulin doses
• Decision support fro clinicians on therapy corrections
• Better customization of patient-specific values in therapies according to long term
trends and habits
• Easier data gathering in clinical trials of new therapies
• Psychological support and pressure ease of patient stress, due to awareness of
continuous monitoring
There had been evidence that virtual coaching can substitute or even improve in-person
visits for both children and adults with type 1 diabetes. Benefits of telemedicine in dia-
betes range from increased attendance at visits to lower overall costs and less time spent
attending visits [15]. mHealth and telemedicine in particular can also overcome future
shortage of diabetes clinicians and give them better chance to work and attend patients
in critical conditions, leaving follow-up patients to virtual approach sessions.
Users report high levels of satisfaction with diabetes apps and increased app usage has
been correlated with improved disease management, both in disease knowledge and in
glucose levels control [16, 17].
1.2.1 State of art of mHealth in diabetes
During the last decade, with the increasing of smartphone popularity and diffusion,
mobile app stores have seen an increase in availability of medical applications. Soon
there had been the need of critically analyze the application’s features in a medical
accuracy perspective.
IDF Europe (International Diabetes Federation European Region) has categorized the
existing applications in a recent article [18] according to their main target audience and
strategies to prevent and manage diabetes:
Tracking/Logging tools to document relevant information including BG, meals, ac-
tivity. This data is used to discover patterns and modify medications.
Nutrition These Apps help patients with food choice, carbohydrate and calorie count-
ing and also help in bolus calculation. This relieves the patients of a a boring and
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repetitive task, while keeping lower the error in manual calculations.
Fitness This apps track physical activity, giving objectives and helping to control
weight.
Connectivity with Platforms Many new apps connect with existing medical devices,
from BG meters, CGM devices and pumps.
Coaching Many applications focus on education and promotion of a healthy lifestyle,
giving general guidance and in some cases, customized coaching.
Social Network Blogs and chats where patients can share their experiences and receive
tips, improving their management operations.
In 2013, Klonoff has summarized the features and problems of the main diabetes appli-
cations at the time [3]. Already in 2013 there were more than 500 applications resulting
in diabetes filtering on the Apple Store [19] and in 2017 the number went up to 1200
[15]. Despite the high number of available applications, many of them present various
issues and many have only a blood glucose tracking feature. There is also a general
trend of diminished interest by users in diabetes-related app over time. Huckvale et al.
performed in 2015 a systematic review of insulin dose calculators, with a focus on data
validation and used model consistency [20]. An interesting outcome of this work is that
many calculators have issues, all related to lack of coherent informations that could be
solved with support during development by a clinician.
One of the most successful applications dealing with diabetes management is mySugr,
which has many features and got international prices and certifications [21].
1.2.2 mySugr mobile application
Launched in 2012, the mySugr mobile app was designed to support patients in the
diabetes self-management areas recommended by the American Association of Diabetes
Educators 7 Healthy Behaviors curriculum [22]: healthy eating, being active, monitoring,
taking medication, risk reduction, problem solving, and healthy coping. During the last
years it has become a reference among mobile applications for diabetes care.
The application has some key features like, automatic uploading of data from SMBG
and CGM devices, either directly via Bluetooth or, for instance, Apple Health, and can
also be synced between devices via a cloud-based service. Additionally, insulin data
can be entered manually into the app. Each new entry can be enriched by the user
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with pictures, other information about meals, medications, activities and current mood.
Other information like physical activity levels can be imported automatically from other
apps, adding context to the clinical data. The user has always access to all data with
the ability to download it as CSV, Excel spreadsheets, or PDF report, giving patients,
as well as clinicians, an accurate therapy overview that presents statistics and detailed
logs.
Figure 1.3: mySugr today page with statistics, graph and logbook
The application has also a proactive action: it uses pattern recognition algorithms to
highlight areas of control where the patient should focus his attention. It also has a bolus
calculator in it which has been CE-marked (Conformite´ Europe´ene). It assists in bolus
calculations and carbohydrate corrections in case of a low blood glucose prediction.
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mySugr power and success resides in the mix of psychology and assistance given to users,
not only focus on diabetes data. The whole app has been designed to be visually pleasing
and to give feedbacks to the users of their daily management successes. [21] To keep
patients involved in their disease management the application has a game mechanics
which uses a reward system for each action taken by the patient each day on the app.
The application uses a digital avatar of the disease that the user combats with each
measure and entry uploaded.
There is also a form of self teaching: users can search and look up their past data
checking which impact each event had on glucose levels. Using this information users
can change their behavior and overcome future difficult situations better.
1.3 Fundamental usability aspects and open issues
To recap what said in this chapter, mobile health will have a big impact on health man-
agement and health system of countries in near future. As said many applications, not
only for diabetes management, are available on mobile stores, but with rare exceptions
those have big usability and clinical relevance issue. Developers of new platforms will
need to take in consideration all previous assessments in order to give to the users a
well built and functioning application that can help their disease management and im-
prove their quality of life. There is also the need of cooperation between developers and
clinicians, but also clinic and hospitals’ managers will have to understand and promote
mobile applications and virtual coaching to improve patients care and reduce mainte-
nance costs. The development process will have to consider user needs, disease-specific
and general, with a long period of application testing on various groups, in order to
guarantee high specs in the final product.
Another key aspect is that are experiencing an always more connected environment,
where all data gathers in data hubs. This will need to be considered also for health data,
with a particular attention to privacy and security. More data from various sources will
allow to build custom therapies for patients, improving even more their lifestyle with
minimum impact. Remote monitoring will be a big part of this process: it will allow lower
waiting times for in-person visits and a direct line between patients and clinicians.
Mobile applications will become a perfect platform for decision support systems, that
will need to be tested in clinical trials. Clinical trials themselves will change the method-
ology of data gathering, using modified versions of existing applications or, in case of
algorithms, ad hoc developed applications.
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This is the context where my thesis was set, with the aim of creating a platform (mobile
app, cloud database and web interface) for data gathering during clinical trials involving
T1D individuals. In particular, once created, this platform will allow also the testing
of algorithms developed by the research group in DEI in Padua, which will build in the
end a decision support system for T1D patients.
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Chapter 2
Project overview and thesis
objectives
During the last year there had been a continuous research of new diabetes management
algorithms (bolus calculators, glycemic prediction, decision support systems...) by the
Bioengineering group at Department of Information Engineering (University of Padua).
In the near future these algorithms will be tested on T1D patients during clinical trials,
so there is the need for an easy to use platform that will enable their use and will allow
gathering data for later analysis.
The main objective of this thesis is to develop a platform prototype to fulfill this need.
The main requirement of the platform is thus to allow data gathering during clinical
trials of new possible algorithms for diabetes therapy support, and to create a database
that will allow to gather those data for later use, e.g. in further simulations and studies.
This can be divided in four smaller objectives:
1. Develop a mobile application for data gathering by the patient during clinical trials,
with ability to easily add modules for future testing (e.g algorithms for decision
support);
2. Give the patient during platform usage an enriching therapy management expe-
rience, with statistics and trends that will allow the patient to learn from the
past.
3. Give the clinician the ability to monitor in real time all his patients.
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4. Create a database that will allow for later use of the gather data for later use, e.g.
as dataset for future analysis and studies.
By gathering data from the patient we allow him to know his statistics and improvements
in the glycemic level control. With the data we can potentially give him some decision
support information via newly developed algorithms and thus making him feel safer and
more monitored in his everyday life.
Uploading all data to a cloud database, it enables the clinician to monitor trends and,
in case of need, call the patient for adjusting his therapy and analyze his progress in the
trial.
With specific regard of clinical trials the main need is the ability of choosing which kind
of data to gather for each patient, while keeping everything anonymous and easy to
analyze later.
2.1 Platform overall structure
The whole platform to be developed is composed of three different main sub-systems: a
mobile application, a cloud database and a website. As shown in Figure 2.1 the project
has a common model interface, which will be the common basis of the entities involved
between all project parts. The cloud database will conain all gathered data during trials,
with all patient specific variables and will be communicating through a REST API with
the mobile application and the web interface, the other two main parts of the project.
The mobile application will allow the patient to upload new data to the cloud database
and to review his previous data. It will also have a local database for the patient to
save data in case of network unavailability. The web interface will allow the clinician to
monitor all patients in the trial in trial time.
2.1.1 Thesis structure
Starting from the next chapter we will describe the development progress, with focus
on requirements definition for each platform, usability choices and privacy preserva-
tion.
Before delving into project specific development, we will introduce, in Chapter 3, the
framework and language that has been used and why it has been chosen. In the Appendix
there will be some code samples of the language and implementations of small pieces of
logic. In Chapter 4, we will show the chosen model for data and all relations between data
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Common Model
Cloud Database
Mobile Application
Web Interface
Figure 2.1: Platform structure overview. There are three elements all communicating
through a restful API: the mobile application, the cloud database and the web interface
types. There will be a section on how the security and privacy problem was dealt and a
section describing the API that allows communications between all platform elements.
Chapter 5, will be focused on a description of the mobile application with emphasis on
user interaction and interface. In Chapter 6, we will describe the clinician monitoring
website, with an introduction on patient creation process. In Chapter 7, there is an
analysis of a small beta testing session that allowed to try the application in real life
scenario. Finally in Chapter 8, results will be summarized with a look on possible future
development possibilities.
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Chapter 3
Development framework and
language
In the following chapter we will discuss the decision process behind the choice of the
development framework and language to be used. First we will describe the chosen
language, then the framework that uses that language in development.
3.1 Rationale of framework choice
Before starting the actual development, we needed to choose which language to use for
mobile applications. One of the main problems of medical mobile applications is that not
all patients may have the needed smartphone to support the app [10], thus we wanted
to have the widest spectrum of mobile systems supported. There was the possibility of
writing two different codes, one for Android and one for iOS, with the same functionality.
It would have meant to develop the same features in both platforms and to later maintain
two different source codes.
In early 2015 Facebook announced React Native, a framework for building native ap-
plications writing a single Javascript code. In late 2018 Google announced its own
framework, called Flutter, which uses Dart as language.
The choice ended on Flutter because of Dart’s support for web and desktop applications,
allowing wide support and multi-platform development. This meant that writing a single
code, one could have working applications on mobile, desktop and a working website.
It was exactly what we needed for a fast and stable development. Moreover Flutter has
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many Widgets that mimic the native look and functionality of the native UI elements,
and Flutter doesn’t need any platform specific optimization, as React might need [23],
because it is already compiled in native code. Another advantage is that usually to see
a change in the code take effect the application must restart and rebuild from scratch,
meaning long periods of inactivity because of code compilation. With ”hot reload”,
all changes take effect in seconds, just saving the source code gives a visible effect on
the application. Flutter also supports state preserving hot reload, which means no
application state is lost.
3.2 Dart
Dart is an object-oriented, class defined, garbage-collected language. The Dart virtual
machine features a just-in-time (JIT) execution engine1. While writing and debugging
an app, Just In Time compilation allows for ”hot reload”, with which modifications to
source files can be injected into a running application.[24]
Dart’s execution engine can also be AOT (Ahead Of Time). Dart’s code is compiled to
a fast, predictable, native code, which allows almost all of Flutter to be written in Dart.
This not only makes Flutter fast, but virtually everything (including all the widgets)
can be customized at very low level. Dart makes it easier to create smooth animations
and transitions that run at 60fps. Dart can do object allocation and garbage collection
without UI locks and freezes.
Moreover, Dart is declarative and thus it allows to avoid the need for a separate declar-
ative layout language like JSX or XML, or separate visual interface builders. All the
layout is done in one language and in the same file, thus it is easy to have advanced
tooling that makes layout designed and built very fast.
A layout example code can be found in Appendix A.
3.3 Flutter framework: a brief introducion
3.3.1 Everything is a Widget
The 4th December 2018, Google has announced the first stable release of Flutter frame-
work. Flutter allows a fast development for both mobile platforms and, lately also for
1Just In Time compilation means that the compiler runs during the execution, not before starting
the application
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web and desktop. The fundamental brick of Flutter is the Widget: everything is a
Widget. Flutter development consists in describing the layout of the application on the
device, composing, assembling and creating Widgets from other Widgets. All Widgets
are organized in a tree, which has as root the build() method of the main application
Widget. Each leaf of the tree is child of his parent widget, which builds itself after his
children. A documentation page says: ”A widget is an immutable description of part
of a user interface.” [25]. However, there are many types of Widgets in Flutter, and
during common development one cannot see or touch all of them. A string is a Widget
(Text), but so is its style (TextStyle), which defines things like size, color, font family
and weight. There are Widgets that represent things, others that represent character-
istics (like TextStyle) and even others that perform actions. Complex widgets can be
created by combining many simpler ones, and an app is actually just the largest Widget
of them all (usually called MyApp) which contains all the other Widgets. In Figure 3.3.1
it is shown the widget tree that underlays the UI element shown. The UI is a simple
row containing three buttons with an icon and a description each. This is translated
in the Widget structure by having a repetition of three identical structures, building
the button itself, all set in a row contained in a Container Widget that allows for some
dimension properties to be set.
3.3.2 Hello World
The code in Listing 3.1 builds, for example, the standard Hello World application, which
consists in application which displays a string in center of the screen. It is evident how
the ”everything is a widget” statement is applied here. The HelloWorldApp is the root
Widget, and builds the application UI with a bar (i.e. AppBar) containing the title
(which will be positioned on the screen according to the target platform style) and a
body containing the centered text. Widget in code can be easily identified by a capital
letter.
The power of Flutter resides also in the always increasing packages library. Packages are
pieces of code, usually consisting in custom Widgets providing custom functionalities,
layouts and styles. There are some official packages, such as Material, Cupertino and
IO, which provide basic functionalities (i.e. predesigned UI elements in accordance
to Material design, iOS design guidelines, platform file integration, respectively), but
everyone can build his own package and distribute it through pub.dev website.
There are two main categories of Widget in Flutter: Stateless and Stateful. Widget
themselves don’t contain any state information, being immutable and having all their
20 3. DEVELOPMENT FRAMEWORK AND LANGUAGE
(a)
(b)
Figure 3.1: UI element (a) and its Widget tree description (b). In (b) it is evident how
each Widget can have a child and a parent: this ends up in a tree structure.
fields as final. To add a state information to a Widget, the Stateful Widget has to be
used. It creates a State object, which stores information and gives the Widget itself
the information needed for building and displaying. Stateless Widget are built the same
every time with the configuration provided. Stateful Widget on the other hand, can
be built several times during execution, each time containing different informations and
possibly displaying differently.
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1 import ’package:flutter/material.dart ’;
2
3 void main() => runApp(HelloWorldApp ());
4
5 class HelloWorldApp extends StatelessWidget {
6 @override
7 Widget build(BuildContext context) {
8 return MaterialApp(
9 title: ’Hello World App ’,
10 home: Scaffold(
11 appBar: AppBar(
12 title: Text(’Hello World App ’),
13 ),
14 body: Center(
15 child: Text(’Hello World ’),
16 ),
17 ),
18 );
19 }
20 }
Listing 3.1: Hello World app code
3.3.3 Using Flutter for web app development
During the Google IO19 in May 2019, Google announced Flutter support for web. Flut-
ter for the web is a code-compatible implementation of Flutter that is rendered using
standards-based web technologies: HTML, CSS, and JavaScript. This means that exist-
ing Flutter code written in Dart can be compiled and executed in a web browser, and be
deployed to any web server. All features of Flutter can work also in web environment.
With Flutter version 1.9, the Flutter SDK actually contains web support in it, but is
still in alpha phase, thus not all functionalities are working and will certainly change
with future releases. As for version 1.9, Flutter for Web is not ready for production, but
the developers can start developing websites written in Flutter and Dart.
In the next chapter we will analyze and show how the model of the data for the platform
has been developed.
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Chapter 4
Definition of the common model
used in the project
In this chapter we will define the model used in the platform. The model has been
defined once for all platform elements, in order to have consistent data. The model has
to respect some requirements, such as high security level and modularity.
4.1 A fundamental requirements: security and privacy
Medical data are very sensitive, thus there is the need of some considerations in order
to ensure that patient’s data is not exposed and in case of stolen data, it wouldn’t be
possible to know which patient logged the data.
This means that all data must be anonymous and data communication has to be secured.
This is obtained with, as will be explained in the next section, identification of all
information by an id, which is assigned to the patient during its registration in the
clinical trial.
To guarantee these aspects, as it will be better described later, the medic registers the
patient in the trial via his web interface, inserting only patient’s birth date and gender.
The system returns an id that will allow the medic to later map the real patient to the
data, and a password that will be used by the patient to log in on the mobile application.
This way only the medic knows the correspondence between id and patient, saving it by
himself.
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4.2 Database structure: E-R Schema
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Figure 4.1: Entity-Relation schema of the application model
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4.2.1 Entities
Because of the target of this project, there are some subjects that are elements of the
problem: the Medic and the Patient.
Of course the data to be gathered is an element of the project and needs some formal-
ization in the structure of each kind of data and we needed to decide on which kind of
data to focus. As will be discussed later, the data types needed for sure are:
• Glucose measure
• Insulin dose
• Meal
To this some other came into play later in the development because of their importance
in glucose concentration control:
• Activity
• Sleep
• Menstrual period
Trial was not considered an Entity at this time of development, because of the need to
formally define its characteristics and properties. It will be inserted in the schema in
future versions.
4.2.2 Relations
Entities relations are:
• Medic and Patient are in a n-1 relation. In fact the same medic can follow many
patients at once. This means that medic field in patient entity is a foreign key.
• Patient and all data types are in a 1-n relation. This means that patient field for
each data entity is its foreign key.
4.3 Database implementation using SQL
The complete tables structure considering all attributes is the following:
Medic id
The Medic entity has only the id field, which is its primary key.
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Patient id, birth date, gender, medic, trial code, test group, clinic code, trial patient id
The Patient entity has the id field, its primary key and internally used, patient’s
gender and birth date are useful informations for data analysis. Patients have also
information about the trial.
As seen all data types have the same structure with the timing, the patient and a value.
There are also some metadata specific of the single type of data and a note field which
is present but not always allowed for editing.
Glucose time, patient, value, moment, note
Glucose’s moment field describes the meal relative timing of the glucose measure:
• Pre-meal: the measure has been performed before eating
• Post-meal: the measure has been performed after eating
• Fasting: the measure has been performed hours distant from any eating
Insulin time, patient, value, type, velocity, note
Insulin’s type field describes whether the injection is a correction bolus or made
at meal time:
• Correction bolus: the insulin injection is a correction made to better control
blood glucose levels
• Meal time: the insulin injection has been done corresponding to a meal
while the velocity is for the effective speed of used insulin:
• Fast: the insulin action speed is fast
• Slow: the insulin action speed is slow
Meal time, patient, value, meal type, absorption speed, composition, note
Meal’s type field describes the kind of meal:
• Breakfast: a meal in the early morning
• Lunch: a meal at mid-day
• Dinner: a meal in the evening
• Snack: a meal in another time of day
• Night-time snack: a meal during the night
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• Hypo-treatment: a meal needed to recover from or avoid a hypoglycemic event
absorption speed of the meal:
• Fast: usually simple carbohydrates
• Slow: usually complex carbohydrates
composition is useful for defining if the meal was carbohydrates only or had a
mixed composition:
• Carbohydrates only
• Mixed, one or more can be selected among:
– Carbohydrates
– Fat
– Proteins
Activity start time, end time, patient, aerobic, duration, note
Activity’s aerobic field is a flag for whether the activity was aerobic or not.
Sleep start time, end time, patient, duration, category, note
Sleep’s category field is based on a standard description:
• In bed
• Sleeping
• Awake
Menstrual period start time, end time, patient, note
The database has been setup with the code shown in Listing 4.1.
CREATE TABLE patients (
id INTEGER (11) NOT NULL AUTO_INCREMENT ,
birth_date VARCHAR (191) NOT NULL ,
gender VARCHAR (191) NOT NULL ,
medic INTEGER (11) NOT NULL ,
PWD INTEGER (11) NOT NULL ,
created_at TIMESTAMP NULL DEFAULT NULL ,
updated_at TIMESTAMP NULL DEFAULT NULL ,
trial_code VARCHAR (191) DEFAULT NULL ,
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test_group TINYINTEGER (1) DEFAULT NULL ,
clinic_code VARCHAR (191) DEFAULT NULL ,
trial_patient_id INTEGER (11) DEFAULT NULL ,
PRIMARY KEY (id)
);
CREATE TABLE medics (
id INTEGER (11) NOT NULL AUTO_INCREMENT ,
name VARCHAR (191) NOT NULL ,
PWD VARCHAR (191) NOT NULL ,
PRIMARY KEY (id)
);
CREATE TABLE measures (
time DATETIME NOT NULL ,
patient INTEGER (11) NOT NULL ,
glucose DOUBLE NOT NULL ,
moment VARCHAR (191) DEFAULT NULL ,
note VARCHAR (191) DEFAULT NULL ,
PRIMARY KEY (time),
FOREIGN KEY (patient) REFERENCES patients (id) ON DELETE
CASCADE
);
CREATE TABLE insulins (
time DATETIME NOT NULL ,
patient INTEGER (11) NOT NULL ,
insulin DOUBLE NOT NULL ,
type VARCHAR (191) DEFAULT NULL ,
speed VARCHAR (191) DEFAULT NULL ,
note VARCHAR (191) DEFAULT NULL ,
PRIMARY KEY (time),
KEY insulins_patient_foreign (patient),
FOREIGN KEY (patient) REFERENCES patients (id) ON DELETE
CASCADE
);
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CREATE TABLE meals (
time DATETIME NOT NULL ,
patient INTEGER (11) NOT NULL ,
carbohydrates DOUBLE NOT NULL ,
mealTime VARCHAR (191) DEFAULT NULL ,
assorbitionSpeed VARCHAR (191) DEFAULT NULL ,
note VARCHAR (191) DEFAULT NULL ,
composition VARCHAR (191) DEFAULT NULL ,
compositionElements VARCHAR (191) DEFAULT NULL ,
PRIMARY KEY (time),
FOREIGN KEY (patient) REFERENCES patients (id) ON DELETE
CASCADE
);
CREATE TABLE activities (
startTime DATETIME NOT NULL ,
patient INTEGER (11) NOT NULL ,
endTime DATETIME NOT NULL ,
aerobic TINYINTEGER (1) NOT NULL ,
duration INTEGER (11) NOT NULL ,
note VARCHAR (191) DEFAULT NULL ,
PRIMARY KEY (startTime),
FOREIGN KEY (patient) REFERENCES patients (id) ON DELETE
CASCADE
);
CREATE TABLE sleeps (
startTime DATETIME NOT NULL ,
patient INTEGER (11) NOT NULL ,
endTime DATETIME NOT NULL ,
duration INTEGER (11) NOT NULL ,
category VARCHAR (191) NOT NULL ,
note VARCHAR (191) DEFAULT NULL ,
PRIMARY KEY (startTime),
FOREIGN KEY (patient) REFERENCES patients (id) ON DELETE
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CASCADE
);
CREATE TABLE menstrual_periods (
startTime DATETIME NOT NULL ,
patient INTEGER (11) NOT NULL ,
endTime DATETIME NOT NULL ,
note VARCHAR (191) DEFAULT NULL ,
PRIMARY KEY (startTime),
FOREIGN KEY (patient) REFERENCES patients (id) ON DELETE
CASCADE
);
Listing 4.1: Database tables creation queries
In the following chapter we will see how this model has been used in the mobile appli-
cation development.
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Figure 4.2: Created tables schema with all attributes, keys and relations shown
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Chapter 5
SuGluLog: the mobile
application
In this chapter we will describe the mobile application that has been developed, with a
description of his screens and focusing on the user interaction possibilities.
5.1 Mobile application requirements
The mobile application is the core of the platform. It has to be built around patients
and their experience.
The user experience needs to be as smooth as possible, and allow fast and precise data
insertion while having a robust infrastructure behind. Before starting the development,
some state of art research was needed and had been performed.
5.1.1 Requirements
Starting from Table 7 in [3], reported in Table 5.1 we have set up a list of needed
features:
• The basic data types connected with diabetes are of course blood glucose levels, in-
sulin doses and meals intakes, to those we have added activity, sleep and menstrual
period tracking
• Every event needs to be pinned in time in order to be able to be used in statistics
and trends analysis. Each event cannot be only a numerical value but is useful to
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1. Glucose tracking
2. Carbohydrate tracking
3. Insulin/medicine tracking
4. Activity tracking
5. Weight tracking
6. Blood pressure tracking
7. Meal-time tagging
8. Preset notes
9. Custom notes
10. Food database
11. Color coded for hypoglycemia/hyperglycemia
12. Trend chart length
13. Widescreen mode
14. Logbook view
15. Direct entry from logbook
16. Averages
17. Standard deviation
18. Email composer
19. Target range settings
20. Background themes
21. Email (comma-separated values)
22. AutoSync to Website
Table 5.1: Data Management Features of the 12 Diabetes Mobile Applications with the
Highest Ratings at the Apple iTunes Store as of October 9, 2009
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attach to it some data type specific tags and custom notes
• A fast and easy data representation can help the patient understanding his trends
in the short and long period, potentially leading to the decision to edit his lifestyle
to improve the glucose control
• Basic statistical information, such as averages, variability, maximum and mini-
mum, counters, can be useful if the patient knows his control target
• A logbook listing all data gathered allows the patient to edit wrong entries im-
proving data quality
• Therapy specific data, such as target ranges and basal insulin, can improve the
quality of data and tracking them is useful to the patient for reference
• A cloud data synchronization allows for remote monitoring by the clinician and
easier access to dataset by researchers
• A printable and sharable Pdf report of the last 14 days can improve the com-
munication between patient and clinician, reducing the need of in person control
visits.
5.2 Design choices
5.2.1 Platform name
The name of the platform had to allow for a website URL that was not already used and
the name had not to be linked to any existent organization or project in any field.
After some research on the internet, the choice ended up on SuGluLog, which stands
for Sugar Glucose Logger.
5.2.2 Platform logo
The logo is the first element of the application that is visualized by the user, so it has
to be clear and descriptive of the application. This platform’s logo was chosen to be
the stylized icon of a sugar container with the name of the platform as label (Figure
5.1).
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Figure 5.1: Platform logo
5.2.3 General user interface design
The User Interface (UI) design during the development and prototype release phase had
been focused on functionality and will be refined and restyled in future development
phases.
The main interface color is light green with white as emphasis color. This allows for
a high contrast and easy to read text. Most elements of the application respect the
platform specific elements’ style, while custom buttons and informative elements had
been designed from scratch.
A big influence in the design of the mobile application design had come from mySugr
and a famous menstrual cycle tracker app Clue.
The website got a restyle in the final development phase with a card oriented design
that will be discussed in chapter 6.
The whole platform is only localized in Italian because the target of use is in Italy, it
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will be localized at least in english in future releases.
5.3 Screens
The application screens structure is organized as in Figure 5.2.
Homepage
Today
Data Insertion and Editing
Settings
Notiﬁcations Insulin TherapyTrial Settings
Calendar
Month Week Day
Report
Share screen
Figure 5.2: General screens organization. The user has the possibility to navigate be-
tween the tree main screens (Today, Calendar and Report) from the homepage and from
those to the other screens
As can be seen the user lands on the Homepage which then is divided in three subscreens
that will be described in the next sections.
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Login The login page, not shown, is a simple form with a birthday and password
fields. The patient logs in using as password the code generated by the web interface
as will be described later. In case of successful login the application downloads all
previously uploaded data of that patient: this is useful in case of smartphone change or
log out.
5.3.1 Today
The today screen is the most used one, because from here the patient can add new data
and see some statistics of the last 24 hours.
Figure 5.3: Today Screen, the most used screen by the user during the typical application
usage
The layout is simple, yet informative: on top there is the AppBar, where the date is
shown with two buttons, one for manual syncing of data, and one for patient informations
and settings.
Below there is a graph showing the last 24 hours data of most the trackable data types.
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The graph shows in green the glicemic curve with in grey the suboptimal ranges, insulin
as blue dots below and meal as yellow dots. Sleep time is marked as blue area and
activity period as red area.
Under the graph there is a grid with some statistics of the period and the plus button
that leads to the Data insertion screen. The shown statistics are: the last glucose and
insulin measures, an average on the period, the number of hyper-hypo events and the
maximum glucose variation. This statistics has been chosen because they allow a fast
understanding of the last day curve.
5.3.2 Data insertion and editing screen
The user reaches this screen after tapping on the plus button in the Today screen or
pressing on an entry in the log view, which allows the patient to edit the selected en-
try.
The graphical structure of this screen has been inspired by the adding screen of Clue, a
well-known menstrual cycle tracking application.
Having multiple data types, the page is divided in six tabs, that can be accessed from
the TabBar below the AppBar. The general layout of each tab is similar. At the top
there is the date and time of the event on which, by tapping on it, the patient can choose
another time and day. Below there is a textfield for the measure’s numeric value and
below there are some icons to select the metadata needed for the measure. The metadata
icon has been chosen to be informative at first sight, but there is a description below
each button. All inserted data is validated during insertion and before saving.
As said, this screen can be reached also from the Day Calendar View by pressing on a
log entry. This fills all fields of the pressed log entry. This allows the patient to edit a
previously inserted data. The editing time is saved in order to recognize during analysis
which data has been later modified.
After all data has been inserted the user can tap the button in the Appbar on top to
save it locally and automatically the application tries to upload it to the cloud.
5.3.3 Calendar
The calendar tab is useful and informative to the patient because it shows statistics of
past periods in an understandable way, which allows the patient to keep track of his
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(a) Glucose measure insertion tab (b) Sleep data insertion tab
Figure 5.4: Data insertion screen tabs, one for each tracked data type and all with the
same layout
improvements in the diabetes management and therapy progression. The patient can
choose which view to see using the tab selector in the Appbar.
Month view The month view is the starting view of the calendar tab. In this subtab
there is the month calendar and below it some statistics.
Week view The week view is the second view of the calendar tab. In this subtab
there is the week calendar, a graph and below it some statistics.
Day view The day view is the third view of the calendar tab. In this subtab there is
the selected day graph and below it the day logbook.
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(a) Month view (b) Week view
(c) Day view (d) Log view
Figure 5.5: Calendar views showing different layout and statistics of the selected period
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5.3.4 Report
The pdf report page allows the patient to export and send a PDF report that summarizes
the last 14 days of monitoring. The report is structured as proposed in [26]. An example
is shown in Figure 5.7. The structure has been designed in order to give the medic a
easy to read report with all information needed to understand patient control quality in
the period.
On top there are some patient informations, below it there are on the left the metrics and
their target values used in the report along with some statistics on the gathered data.
On the right there is a bar chart showing the percentage of time spent by the patient in
each glucose level range. Last there is a time graph, showing a 24 hours period where
it is plotted the median of the glicemic value in that same hour of day throughout the
period with quartiles. This is very important because it allows to recognize patterns
during the last 14 days and thus analyze and solve them.
Figure 5.6: PDF report generation screen. Here the patient can gather all needed data
to produce a report to share with the clinician
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AGP Report
Nome/Id PD00123
Medico
STATISTICHE E OBIETTIVI TEMPO IN RANGE
15/11/2019 - 29/11/2019 15 giorni
Misure giornaliere medie 29
------------------
Range della glicemia Target (% delle misure)
In target 70-180 mg/dL Più del 70%
Sotto 70 mg/dL Meno del 4%
Sotto 54 mg/dL Meno del 1%
Sopra 180 mg/dL Meno del 25%
Sopra 250 mg/dL Meno del 5%
Un miglioramento del 5% nel tempo in range 70-180 mg/dL è di rilevanza clinica.
------------------
Glicemia media 171 mg/dL
Glucose management indicator (GMI) 7.4%
Variabilità glicemica 44.1%
Definita come percentuale del coefficiente di variazione (%CV), target <=36%
Very High (>250 mg/dL) 19.1%
250 High (181-250 mg/dL) 29.2%
180 Target Range (70-180 mg/dL) 40.7%
70 Low (54-69 mg/dL) 5.5%
54 Very Low (<54 mg/dL) 5.5%
PROFILO AMBULATORIALE DEL GLUCOSIO (AGP)
L'AGP è un sommario dei valori di glucosio per il periodo del report, con mediana (50%) e altri percentili mostrati come se fosse un singolo giorno).
Figure 5.7: PDF report example produced with sample data
44 5. SUGLULOG: THE MOBILE APPLICATION
5.3.5 Settings
The settings screen can be reached from the Today page using the button on the top
right. This screen allows the patient to change some settings like which kind of data to
gather, specific to each trial, the hyperglycemia and hypoglycemia thresholds and the
kind of insulin therapy. This screen is also where the patient can access the notification
menu and can log out of the application.
Figure 5.8: Settings screen. From this screen the patient can set his glycemic control
targets and the insulin therapy type
Trial Settings Each clinical trial can have different kind of data required to be gath-
ered. This screen allows the patient to choose which one he wants to track. This will
possibly chosen by the clinician responsible for the trial.
In future versions the clinician will choose what to track for the patient and will not
allow personal choices to track less data kinds than the one needed for the trial.
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Notifications During first tests, it has been noticed how it is critical that the patient
remembers to log data during the day. To increase the appliance to the trial and the
logging procedure, it has been implemented a local notification system, that can be set
up by the patient himself. This notifies the patient in specific times during the day to
log important data.
Figure 5.9: Notifications edit screen. From this screen the user can set up notifications
to remember himself to add new data on the platform
In future versions there will be the possibility to improve the system, setting up a learning
algorithm which will notify the patient based on habits and, when implemented, glucose
variations read by the CGM sensor.
Insulin therapy There are few different insulin therapy types. The main purpose of
this menu is to allow the patient to insert and track his basal insulin doses or pump
infusions. If the patient has selected pump or basal pen, a new button comes up on the
screen, which leads to a new page where the patient can add the pair time-quantity for
basal insulin. By now this is only used for tracking purpose, in future versions it will be
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integrated in algorithms and in gathered data.
Figure 5.10: Insulin therapy screen where the patient can insert and edit his basal insulin
therapy
5.4 Automatic data synchronization
The monitoring activity by the clinician is possible only if the data inserted by the pa-
tient lands on the server database. This is done automatically each time a new data is
added by the patient, but the patient has the ability to manually synchronize all missing
data. At current Flutter development state, the background activity of the application
is not yet stable, and thus it was not implemented and automatic synchronization in
background. It will be implemented easily when the background application task man-
agement will be optimized.
In the next chapter we will show how the data added by the patient with the application
can be seen by the clinician in real time.
Chapter 6
Website
In the following chapter we will describe the online part of the platform, defining the
requirements, the infrastructure that allows all communications and the actual web
platform.
6.1 Web requirements
On the web platform the main objective is to allow the clinician to have under control
all his patients at a glance. The website will allow the clinician to add a new patient in
the system and, in future, set his tracking objectives for the specific clinical trial.
On load, the website shows a login form, where the clinician can log in with his identifier
code and password. After log in the clinician is redirected to the main interface.
In order to communicate with the server to query all data needed an API has been
developed.
6.2 Restful API
The restful API has been written using Lumen, a micro-framework of Laravel.
The main role of the API is to allow connection between the underlaying cloud database
and the external environment, as shown in Figure 6.1. The API will be used by both the
application and the website to update and request data on the cloud database.
Lumen allows for some Middleware, a class that intercepts requests and performs ac-
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Figure 6.1: Restful API typical structure and functionality. It allows communications
between devices and cloud data with HTTP requests made by each client
tions before the actual request is handled. In this project a Middleware was used for
authentication of requests and was provided by an external source [27].
The language used is PHP and the code needs to represent the data model, describe the
database tables, with migrations, and all queries needed. In Lumen this is done with
the following modules:
Model In order to make the API know the data structure, a model of each table has
to be defined. This allow Controllers to know how the data is presented and how to
work with it.
Migrations Migrations are where there is the definition of tables, with their columns,
keys and relations. This migrations are executed on the database and stored in a separate
table to know all structural modifications of the database.
Controllers Controllers are the classes responsible for querying the database. In a
controller there are all commands needed for a specific data request, insertion, update
and deletion. Here it is where all the logic is written. Lumen uses Eloquent for faster
and better query writing. Eloquent is an Object-Relation Mapping language which uses
a model for each table to build queries in a more readable and easier to write way.
Routes Routes are the definition or the URL needed for a certain query. In Lumen
this are defined in a file appending strings to the main URL. This can be done in groups
to have a better control over the routes and here can be defined the HTTP method to
be used for each route. In this project most re quests are made with POST method to
hide informations in the URL and allow complex bodies to the requests.
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In appendix A.2 there are some code examples of the previously described elements.
6.3 Interface
The prototype interface is built around the clinician experience.
As can be seen in Figure 6.2 it can be divided in three main sections.
1. The title bar with on the right the clinician profile button. It allows the clinician
to log out, and in future updates to check and edit his profile and trials he attends
to.
2. A navigation menu where the clinician can select the patient to monitor and add
new one. Patients are identified with their unique id. In future updates it will be
possible to filter patients by trial.
3. The selected patient informative section which contains a graph and some statistics
of the day selected with the arrows above. Clicking on the date a pop up is shown
containing a calendar for faster day selection.
• The chart has the same characteristics of the one in the application, in fact,
thanks to Flutter framework, the code is the same with only few aesthetics
changes.
• A statistics collection showing blood glucose mean and maximum variation,
the number of hyper-glycemic and hypo-glycemic events and the total insulin
and carbohydrates of the day.
6.3.1 Responsive layout
A website has to be accessible from different platforms, ranging from a desktop computer
to a smartphone. Each one of this devices has different screen dimensions, thus the layout
has to change. Three different layouts have been identified with the screen width (in
pixels) as distinction criterion, which will be discussed in the next paragraphs.
Desktop screen (width ≥ 1200px), Figure 6.2 The layout for the widest screen is
horizontally organized. The navigation bar is always available on the left of the screen,
while in the center there is the information panel with the chart and statistics cards side
by side.
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Tablet screen (width between 800 px and 1200 px), Figure 6.3 Medium
screen’s layout focuses the attention more on the information panel, moving the navi-
gation menu in a drawer, that can be open with a button at the top-left of the screen.
Statistics card are moved below the chart to increase readability.
Phone screen (width < 800px), Figure 6.4 Small screen layout is vertical oriented
and is intended for smartphone visualization. Because of the small screen dimension,
the chart has been removed and only statistics are shown. This has been chosen to allow
clinician to consult the platform from their smartphone as needed, but the main usage
of the platform is intended to be on a desktop or tablet environment.
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Figure 6.2: Large screen site layout with all UI element always shown: the list of patients
is always available for the clinician on the left of the screen
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Figure 6.3: Medium screen site layout, where the patient list has been moved to a drawer
in order to accomodate for smaller screen size
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Figure 6.4: Small screen layout, where the only shown element is the statistics box.
This has been decided to allow the clinician to see patient’s data from his phone too,
but because of the screen size it was not possible to show all information
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6.3.2 New patient dialog
The clinician has the ability to add new patients in the platform for a specific clinical
trial. Clicking on the plus button on the navigation menu a dialog comes up.
Figure 6.5: New patient dialog asking all needed data of the specific clinical trial and
patient informations
The dialog has a form asking some informations to the clinician: the birthday, gender of
the patient. Alongside this information the clinician has to insert the identifier code of
the clinical center where he is in care and the trial code the patient will attend.
On submit all inserted data is validated and then a new patient is inserted in the database
and a new dialog is shown to the clinician. It contains a generated password code and
the trial-id of the patient built as CCCTTTFPPP where CCC is the identifier of the
medical clinic, TTT the identifier of the trial, F is a flag for control or test group and
PPP is the identifier of the patient.
6.4 Login and patient creation
On the website the clinician has his own personal profile and can monitor only the
patients he has in care. To log in the clinician uses his unique identification number and
a numerical password. Furthermore all requests made by the website are authenticated
internally and made with the POST method. After patient creation, the clinician receives
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the id of the patient, which he has to save somewhere to remember the binding between
code and physical patient, and the password which will be used by the patient.
The patient logs on the application with his birth date and the password generated by
the system. This process sets the id of the patient internally to the application, that
will use the id to attach each new data to the patient setting the id as foreign key of the
data type table as described before.
In the next chapter there will be the space for the analysis of a brief beta testing session,
made in order to proof that the platform is usable in all its parts.
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Chapter 7
Beta testing
The last phase of the project has been a small beta testing session. It involved a diabetic
subject who has been using the application for seven days. This short testing session
allowed to prove the usability of the platform and solve bugs that would come out during
long term use of the application. During the session few bugs have been encountered and
reported to be solved. this included error in the login procedure and synchronization after
first login. Report generation also had some issues that have been easily solved.
In Figure 7.1 it is shown the final report with all data of the testing session. The report
shows an excellent glicemic control, with a high time in target. The graph in the report
has data only during the day and an average of two measures a day. The graph shows
some variability in glucose levels during the day and proves that the report building
works.
The general feedback on the application is positive. The usability is good and all shown
statistics allowed the subject to understand more his levels throughout the testing ses-
sion. The whole application has been reported to be intuitive in use, but a helper or
showcase function could be useful to discover every feature of the application. The
subject reported a good experience in using the interface for data uploading, giving
some useful advices for future improvements. For example insulin velocity metadata
should be automatically chosen according to the specific patient settings, in fact pump
or micro-infuser users usually get slow fast acting insulin, while pen users slow acting
insulin. The subject reported also that during real life usage the metadata requested
in meal insertion are usually the same and rarely considered. It has been proposed to
show those metadata during specific trials only. Furthermore has been observed that
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the time selection for past data insertion could be improved setting a five minutes step
in the selector, while at the moment the selector has one minute step. This would allow
for faster time selection and consequent past data update. Some better explanation of
some metadata could be added in order to give the user better understanding of some
of them, such as ”aerobic” activity and ”fasting” time.
The only problem encountered is consistency in use. Notifications are implemented but
not automatically set up, it has been suggested to add default notifications at every
meal time. The subject was already using a micro-infuser, thus it was not important for
him to track data manually on another device. This resulted in a small amount of data
uploaded in the platform. The integration with health applications has to be developed
as the highest priority feature in the near future.
With regards of monitoring, the system works in real time, but at current state the
patient has no ability to know whether the clinician has checked new data. It will be
implemented a system for the patient to check if it has been monitored and for the
clinician if there is new data.
In conclusion the user reported that the application is really useful and helpful for those
who use a manual diary during everyday life. If some new feature, such as automatic data
insertion from other devices (CGM, fitness tracker), will be implemented the application
will become even more useful.
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AGP Report
Nome/Id PD0000011
Medico
STATISTICHE E OBIETTIVI TEMPO IN RANGE
27/11/2019 - 5/12/2019 8 giorni
Misure giornaliere medie 2
------------------
Range della glicemia Target (% delle misure)
In target 70-180 mg/dL Più del 70%
Sotto 70 mg/dL Meno del 4%
Sotto 54 mg/dL Meno del 1%
Sopra 180 mg/dL Meno del 25%
Sopra 250 mg/dL Meno del 5%
Un miglioramento del 5% nel tempo in range 70-180 mg/dL è di rilevanza clinica.
------------------
Glicemia media 118 mg/dL
Glucose management indicator (GMI) 6.1%
Variabilità glicemica 34.5%
Definita come percentuale del coefficiente di variazione (%CV), target <=36%
Very High (>250 mg/dL) 0.0%
250 High (181-250 mg/dL) 0.0%
180 Target Range (70-180 mg/dL) 84.2%
70 Low (54-69 mg/dL) 10.5%
54 Very Low (<54 mg/dL) 5.3%
PROFILO AMBULATORIALE DEL GLUCOSIO (AGP)
L'AGP è un sommario dei valori di glucosio per il periodo del report, con mediana (50%) e altri percentili mostrati come se fosse un singolo giorno).
Figure 7.1: Beta testing session patient generated report with data of eight days
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Chapter 8
Conclusions
mHealth has proven to be extremely useful in T1D therapy and management, in fact
in recent years there has been a boost in research in this field. The aim of this thesis
was to provide a new platform prototype that allows for patient monitoring and data
gathering.
This project has obtained some important results: a new working platform prototype,
usable for clinical trials, has been built and is ready for deployment. We have created a
system that comprehends a cloud database, a mobile application, a web interface and the
infrastructure that allows all communications between this elements. With this platform
the clinician has real time monitoring capabilities of his patients with statistics and the
patient has a mobile application that allows him to track his values and check some
statistics of different time periods. This has been achieved by allowing the patient to
add data manually in the application. All data is automatically uploaded to a cloud
database for later reference and real time monitoring. The application was built trying
to respect all the requirements identified and while giving him an exhaustive access to
all data, the patient interaction is kept at minimum. The website has been developed
to allow the clinician to check all his patients condition in a single place and in an easy
way.
The whole system is modular and built so that it is easy to expand and reshape to the
need of each specific trial. For example adding a new module for a new algorithm in
testing, is as easy as creating a new file that builds the page and some data logic around
it. The communications are one way only, from the patient to the clinician but it will
be interesting to implement some alerts and suggestion that the clinician could send to
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his patient or change his parameters.
This platform prototype can be the starting point of a separate application that could
be widely released which could implement working techniques to give patients a more
integrated decision support system.
8.1 Future development
This project got the platform to a working point, but the whole project is not completed
and many future possible features need to be designed and added.
At current state the application accepts only manual input by the patient. Many pa-
tients have some automatic sensors that measure their blood glucose continuously and it
would be interesting to integrate this sensors in the data gathering platform. The Bio-
engineering research group at DEI has recently signed an agreement with Dexcom, Inc.,
a leader corporation in CGM sensors and diabetes care, which will provide all libraries
and software to transfer in real time data from the sensor to the application. This will
also allow to later implement all algorithms that compose a decision support system that
use real time data.
Many smartphones, smartwatches and wearables nowadays allow tracking of physical
activity, sleep cycle and many other types of information. It would be beneficial for
the dataset and the patient to automatically retrieve this informations from the devices
and integrate them in the platform. The integration would be possible using the health
applications of each operative system. This would allow more complete data for later
analysis and for decision support algorithms.
The platform has been developed and thought because there was the need of a consistent
and easy method for data gathering and patient monitoring during trials of algorithms,
thus all the algorithms will have to be implemented and those will integrate all data
gathered and more information giving to the patient some outputs which will lead to a
decision support system.
Each trial is different in the duration and type of data needed, in the current state the
patient has to choose which data to track. In future versions it would be better to
give the clinician this choice and allow the patient only to add more data types to the
tracking. Moreover the clinician could send notifications to the application with changes
in therapy, thresholds and other information. On the other hand the application could
alert the patient if the blood glucose level are are below or above the safety thresholds
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and send to his clinician a notification to signal the event. This would implement a more
integrated system allowing better patient care and disease treatment.
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Appendix A
Code samples
A.1 Layout example
The following UI element is designed and coded as in Listing A.1.
Figure A.1: Example layout of an UI element
The layout consists in a tree structure with a Container as root Widget. The Container
Widget allows for some customization of the child Widget, in this case some padding
all around the child Row Widget. The Row Widget describes an horizontal sequence of
Widget: the first is a Column (a vertical sequence of Widgets) of two Text Widgets, the
second is an Icon and the third is another Text widget. In order to have the second part
of the row flushed right, the Column Widget is wrapped in an Expanded environment,
which allows the Column to take all the horizontal space available.
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1 Widget titleSection = Container(
2 padding: const EdgeInsets.all (32),
3 child: Row(
4 children: [
5 Expanded(
6 child: Column(
7 crossAxisAlignment: CrossAxisAlignment.start ,
8 children: [
9 Container(
10 padding: const EdgeInsets.only(bottom: 8),
11 child: Text(
12 ’Oeschinen Lake Campground ’,
13 style: TextStyle(
14 fontWeight: FontWeight.bold ,
15 ),
16 ),
17 ),
18 Text(
19 ’Kandersteg , Switzerland ’,
20 style: TextStyle(
21 color: Colors.grey [500] ,
22 ),
23 ),
24 ]),
25 ),
26 Icon(
27 Icons.star ,
28 color: Colors.red[500] ,
29 ),
30 Text(’41’),
31 ],
32 ),
33 );
Listing A.1: Layout example code
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A.2 API examples
A.2.1 Model example
The following code shows the patient model that allows the API to know how to work
with data from the patient table. In the model there is the description of they and the
list of attributes, the password in this case, that are not returned in the JSON format
to a request .
1 class Patient extends Model{
2 protected $primarykey = ’id ’;
3 public $incrementing = false;
4
5 /**
6 * The attributes that are mass assignable.
7 *
8 * @var array
9 */
10 protected $fillable = [
11 ’id ’, ’medic ’, ’gender ’, ’PWD ’, ’birth_date ’, ’
trial_code ’, ’test_group ’, ’clinic_code ’, ’
trial_patient_id ’
12 ];
13
14 /**
15 * The attributes excluded from the model ’s JSON form.
16 *
17 * @var array
18 */
19 protected $hidden = [’PWD ’];
20 }
Listing A.2: Patient model
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A.2.2 Migration example
This following code creates the glucose measures table. It has two functions, one for
upgrade the database schema and one to downgrade it. In the up() function, it defines
all columns needed with their properties and then it defines the primary key and the
foreign key to the patients table.
1 class CreateMeasuresTable extends Migration{
2 public function up(){
3 Schema :: create(’measures ’, function (Blueprint
$table) {
4 $table ->dateTime(’time ’);
5 $table ->integer(’patient ’);
6 $table ->double(’glucose ’);
7 $table ->string(’moment ’)->nullable ();
8 $table ->string(’note ’)->nullable ();
9 $table ->timestamps ();
10 });
11 Schema :: table(’measures ’, function ($table){
12 $table ->primary(’time ’);
13 $table ->foreign(’patient ’)->references(’id ’)->on
(’patients ’)->onDelete(’cascade ’);
14 });
15 }
16
17 public function down(){
18 Schema :: dropIfExists(’measures ’);
19 }
20 }
Listing A.3: Migration example code
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A.2.3 Query example
The following code selects all patients of the specified clinician.
1 public function showMedicPatients(Request $request){
2 return response ()->json(Patient :: where(’medic ’, $request
->input(’medic ’))->get());
3 }
Listing A.4: Query example code
This is equivalent to the SQL query
1 SELECT * FROM patients WHERE medic = medic
where medic variable is extracted from the request body. The result of the query is
formatted in json for better usability and conversion in the application and website.
A.2.4 Routing example
The following code defines the URL ”/api/patients/showAllMedic” to return the result
of the query described in A.2.3. In fact on line 7 there is the definition of the route using
the POST method which calls the PatientController function showMedicPatients.
1 $router ->group(
2 [’prefix ’ => ’api ’, ’middleware ’ => ’client ’],
3 function () use ($router) {
4 $router ->group(
5 [’prefix ’ => ’patients ’],
6 function () use ($router) {
7 $router ->post(’showAllMedic ’, [’uses ’ =>
PatientController@showMedicPatients ’]);
8 }
9 )
10 }
11 )
Listing A.5: Route example code
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